

# Steven de Jong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/398069/publications.pdf>

Version: 2024-02-01

36  
papers

2,397  
citations

257450

24  
h-index

361022

35  
g-index

38  
all docs

38  
docs citations

38  
times ranked

5241  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3745.	4.1	6
2	Abstract 5813: Glycogen synthesis as potential novel target in triple negative breast cancer: Glycogen synthase 1 expression in human breast cancers and the impact of downregulation on proliferation of preclinical models. <i>Cancer Research</i> , 2022, 82, 5813-5813.	0.9	0
3	Satisfaction with social connectedness as a predictor for positive and negative symptoms of psychosis: A PHAMOUS study. <i>Schizophrenia Research</i> , 2021, 238, 121-127.	2.0	2
4	Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 590-601.	4.1	8
5	Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies. <i>Scientific Reports</i> , 2020, 10, 18938.	3.3	4
6	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer <sup>18</sup> F-BMS-986192. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1839-1844.	5.0	37
7	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020, 15, e0235766.	2.5	2
8	Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. <i>Cancer Treatment Reviews</i> , 2020, 88, 102054.	7.7	76
9	Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. <i>Cancer Letters</i> , 2019, 461, 102-111.	7.2	40
10	Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 1530.	4.8	51
11	Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models. <i>Cancers</i> , 2019, 11, 895.	3.7	12
12	miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy. <i>Cells</i> , 2019, 8, 1221.	4.1	39
13	MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. <i>Journal of Pathology</i> , 2019, 249, 52-64.	4.5	117
14	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940.	7.0	35
15	Avenues to molecular imaging of dying cells: Focus on cancer. <i>Medicinal Research Reviews</i> , 2018, 38, 1713-1768.	10.5	30
16	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. <i>Oncogene</i> , 2018, 37, 4611-4625.	5.9	72
17	ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 176-184.	7.4	69
18	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527

#	ARTICLE	IF	CITATIONS
19	Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. <i>BMC Cancer</i> , 2017, 17, 232.	2.6	40
20	<sup>89</sup> Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. <i>MAbs</i> , 2017, 9, 1370-1378.	5.2	20
21	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116.	5.5	44
22	Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and <i>in vivo</i> Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets. <i>Theranostics</i> , 2017, 7, 482-492.	10.0	10
23	ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. <i>Oncotarget</i> , 2017, 8, 45432-45446.	1.8	23
24	Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. <i>Genome Medicine</i> , 2016, 8, 107.	8.2	31
25	Practical Implications of Metacognitively Oriented Psychotherapy in Psychosis. <i>Journal of Nervous and Mental Disease</i> , 2016, 204, 713-716.	1.0	41
26	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. <i>Drug Resistance Updates</i> , 2016, 24, 55-69.	14.4	52
27	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 714-724.	7.0	51
28	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer <sup>89</sup> Zr-imagatuzumab. <i>Oncotarget</i> , 2016, 7, 68111-68121.	1.8	16
29	Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. <i>Scientific Reports</i> , 2015, 5, 14495.	3.3	41
30	Molecular Imaging As a Tool for Drug Development and Trial Design. <i>Journal of Clinical Oncology</i> , 2015, 33, 2585-2587.	1.6	27
31	Targeting FLIP and Mcl-1 using a combination of aspirin and Sorafenib sensitizes colon cancer cells to TRAIL. <i>Journal of Pathology</i> , 2013, 229, 410-421.	4.5	28
32	Targeting Trail Towards the Clinic. <i>Current Drug Targets</i> , 2011, 12, 2079-2090.	2.1	21
33	Metformin: Taking away the candy for cancer?. <i>European Journal of Cancer</i> , 2010, 46, 2369-2380.	2.8	345
34	Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. <i>Journal of Clinical Investigation</i> , 2010, 120, 3594-3605.	8.2	193
35	TRAIL receptor signalling and modulation: Are we on the right TRAIL?. <i>Cancer Treatment Reviews</i> , 2009, 35, 280-288.	7.7	248
36	Low p21/Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. <i>Oncogene</i> , 2004, 23, 4862-4872.	5.9	39